Premature Ejaculation Disorder Market in US 2024-2028

The premature ejaculation disorder market in US is forecasted to grow by USD 478.41 mn during 2023-2028, accelerating at a CAGR of 10.22% during the forecast period. The report on the premature ejaculation disorder market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high efficacy of off-label drugs leading to high usage by people, demand for topical drug therapies to treat premature ejaculation, and growing risk factors causing premature ejaculation.

The premature ejaculation disorder market in US is segmented as below:

By Route Of Administration

Oral
Topical

By Drug Class

SSRIs
PDE5 inhibitors
Amide anesthetics
Others

By Distribution Channel

Prescription
OTC

This study identifies the use of nanotechnology in drug delivery as one of the prime reasons driving the premature ejaculation disorder market in US growth during the next few years. Also, increasing research and development activities and emergence of novel wearable products will lead to sizable demand in the market.

The report on the premature ejaculation disorder market in US covers the following areas:

Premature ejaculation disorder market in US sizing
Premature ejaculation disorder market in US forecast
Premature ejaculation disorder market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premature ejaculation disorder market in US vendors that include Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Prinston Pharmaceutical Inc., Teva Pharmaceutical Industries Ltd., Veru Inc., VIVUS LLC, Aytu BioPharma Inc., Royalty Pharma plc, and Sebela Pharmaceuticals Inc.. Also, the premature ejaculation disorder market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 10: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 11: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%)
Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Premature ejaculation disorder market in US 2018 - 2022
Exhibit 16: Historic Market Size - Data Table on premature ejaculation disorder market in US 2018 - 2022 ($ million)
4.2 Route of Administration Segment Analysis 2018 - 2022
Exhibit 17: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
4.3 Drug Class Segment Analysis 2018 - 2022
Exhibit 18: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.4 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 26: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

6.1 Market segments
Exhibit 27: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 28: Data Table on Route of Administration - Market share 2023-2028 (%)
6.2 Comparison by Route of Administration
Exhibit 29: Chart on Comparison by Route of Administration
Exhibit 30: Data Table on Comparison by Route of Administration
6.3 Oral - Market size and forecast 2023-2028
Exhibit 31: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 32: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibit 33: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 34: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Topical - Market size and forecast 2023-2028
Exhibit 35: Chart on Topical - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
Exhibit 37: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibit 38: Data Table on Topical - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Route of Administration
Exhibit 39: Market opportunity by Route of Administration ($ million)
Exhibit 40: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

7.1 Market segments
Exhibit 41: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 42: Data Table on Drug Class - Market share 2023-2028 (%)
7.2 Comparison by Drug Class
Exhibit 43: Chart on Comparison by Drug Class
Exhibit 44: Data Table on Comparison by Drug Class
7.3 SSRIs - Market size and forecast 2023-2028
Exhibit 45: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibit 46: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibit 47: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibit 48: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)
7.4 PDE5 inhibitors - Market size and forecast 2023-2028
Exhibit 49: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibit 51: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 52: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
7.5 Amide anesthetics - Market size and forecast 2023-2028
Exhibit 53: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibit 55: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibit 56: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)
7.6 Others - Market size and forecast 2023-2028
Exhibit 57: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 59: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 60: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Drug Class
Exhibit 61: Market opportunity by Drug Class ($ million)
Exhibit 62: Data Table on Market opportunity by Drug Class ($ million)

8 Market Segmentation by Distribution Channel

8.1 Market segments
Exhibit 63: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 64: Data Table on Distribution Channel - Market share 2023-2028 (%)
8.2 Comparison by Distribution Channel
Exhibit 65: Chart on Comparison by Distribution Channel
Exhibit 66: Data Table on Comparison by Distribution Channel
8.3 Prescription - Market size and forecast 2023-2028
Exhibit 67: Chart on Prescription - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on Prescription - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on Prescription - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on Prescription - Year-over-year growth 2023-2028 (%)
8.4 OTC - Market size and forecast 2023-2028
Exhibit 71: Chart on OTC - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on OTC - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on OTC - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on OTC - Year-over-year growth 2023-2028 (%)
8.5 Market opportunity by Distribution Channel
Exhibit 75: Market opportunity by Distribution Channel ($ million)
Exhibit 76: Data Table on Market opportunity by Distribution Channel ($ million)

9 Customer Landscape

9.1 Customer landscape overview
Exhibit 77: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 78: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 79: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 80: Overview on factors of disruption
11.4 Industry risks
Exhibit 81: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 82: Vendors covered
12.2 Market positioning of vendors
Exhibit 83: Matrix on vendor position and classification
12.3 Absorption Pharmaceuticals LLC
Exhibit 84: Absorption Pharmaceuticals LLC - Overview
Exhibit 85: Absorption Pharmaceuticals LLC - Product/Service
Exhibit 86: Absorption Pharmaceuticals LLC - Key offerings
12.4 Alembic Pharmaceuticals Ltd.
Exhibit 87: Alembic Pharmaceuticals Ltd. - Overview
Exhibit 88: Alembic Pharmaceuticals Ltd. - Product/Service
Exhibit 89: Alembic Pharmaceuticals Ltd. - Key offerings
12.5 Amneal Pharmaceuticals Inc.
Exhibit 90: Amneal Pharmaceuticals Inc. - Overview
Exhibit 91: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 92: Amneal Pharmaceuticals Inc. - Key news
Exhibit 93: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 94: Amneal Pharmaceuticals Inc. - Segment focus
12.6 Aytu BioPharma Inc.
Exhibit 95: Aytu BioPharma Inc. - Overview
Exhibit 96: Aytu BioPharma Inc. - Product/Service
Exhibit 97: Aytu BioPharma Inc. - Key offerings
12.7 Bayer AG
Exhibit 98: Bayer AG - Overview
Exhibit 99: Bayer AG - Business segments
Exhibit 100: Bayer AG - Key news
Exhibit 101: Bayer AG - Key offerings
Exhibit 102: Bayer AG - Segment focus
12.8 Cipla Ltd.
Exhibit 103: Cipla Ltd. - Overview
Exhibit 104: Cipla Ltd. - Business segments
Exhibit 105: Cipla Ltd. - Key news
Exhibit 106: Cipla Ltd. - Key offerings
Exhibit 107: Cipla Ltd. - Segment focus
12.9 Eli Lilly and Co.
Exhibit 108: Eli Lilly and Co. - Overview
Exhibit 109: Eli Lilly and Co. - Product/Service
Exhibit 110: Eli Lilly and Co. - Key news
Exhibit 111: Eli Lilly and Co. - Key offerings
12.10 Johnson and Johnson
Exhibit 112: Johnson and Johnson - Overview
Exhibit 113: Johnson and Johnson - Business segments
Exhibit 114: Johnson and Johnson - Key news
Exhibit 115: Johnson and Johnson - Key offerings
Exhibit 116: Johnson and Johnson - Segment focus
12.11 NeuroHealing Pharmaceuticals Inc.
Exhibit 117: NeuroHealing Pharmaceuticals Inc. - Overview
Exhibit 118: NeuroHealing Pharmaceuticals Inc. - Product/Service
Exhibit 119: NeuroHealing Pharmaceuticals Inc. - Key offerings
12.12 Novartis AG
Exhibit 120: Novartis AG - Overview
Exhibit 121: Novartis AG - Business segments
Exhibit 122: Novartis AG - Key offerings
Exhibit 123: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 124: Pfizer Inc. - Overview
Exhibit 125: Pfizer Inc. - Product/Service
Exhibit 126: Pfizer Inc. - Key news
Exhibit 127: Pfizer Inc. - Key offerings
12.14 Sebela Pharmaceuticals Inc.
Exhibit 128: Sebela Pharmaceuticals Inc. - Overview
Exhibit 129: Sebela Pharmaceuticals Inc. - Product/Service
Exhibit 130: Sebela Pharmaceuticals Inc. - Key offerings
12.15 Teva Pharmaceutical Industries Ltd.
Exhibit 131: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 132: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 133: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 134: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 135: Teva Pharmaceutical Industries Ltd. - Segment focus
12.16 Veru Inc.
Exhibit 136: Veru Inc. - Overview
Exhibit 137: Veru Inc. - Business segments
Exhibit 138: Veru Inc. - Key offerings
Exhibit 139: Veru Inc. - Segment focus
12.17 VIVUS LLC
Exhibit 140: VIVUS LLC - Overview
Exhibit 141: VIVUS LLC - Product/Service
Exhibit 142: VIVUS LLC - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 143: Inclusions checklist
Exhibit 144: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 145: Currency conversion rates for US$
13.4 Research methodology
Exhibit 146: Research methodology
Exhibit 147: Validation techniques employed for market sizing
Exhibit 148: Information sources
13.5 List of abbreviations
Exhibit 149: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Vendor Market Positioning
Exhibits 8: Parent market
Exhibits 9: Market Characteristics
Exhibits 10: Offerings of vendors included in the market definition
Exhibits 11: Market segments
Exhibits 12: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 13: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 14: Chart on US: Year-over-year growth 2023-2028 (%)
Exhibits 15: Data Table on US: Year-over-year growth 2023-2028 (%)
Exhibits 16: Historic Market Size - Data Table on premature ejaculation disorder market in US 2018 - 2022 ($ million)
Exhibits 17: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits 18: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits 20: Five forces analysis - Comparison between 2023 and 2028
Exhibits 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 23: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 24: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 25: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 26: Chart on Market condition - Five forces 2023 and 2028
Exhibits 27: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits 28: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits 29: Chart on Comparison by Route of Administration
Exhibits 30: Data Table on Comparison by Route of Administration
Exhibits 31: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 32: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits 33: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 34: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 35: Chart on Topical - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
Exhibits 37: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibits 38: Data Table on Topical - Year-over-year growth 2023-2028 (%)
Exhibits 39: Market opportunity by Route of Administration ($ million)
Exhibits 40: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits 41: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits 42: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits 43: Chart on Comparison by Drug Class
Exhibits 44: Data Table on Comparison by Drug Class
Exhibits 45: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibits 46: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibits 47: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibits 48: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibits 49: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibits 51: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits 52: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits 53: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibits 55: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibits 56: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibits 57: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 59: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 60: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 61: Market opportunity by Drug Class ($ million)
Exhibits 62: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 63: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 64: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 65: Chart on Comparison by Distribution Channel
Exhibits 66: Data Table on Comparison by Distribution Channel
Exhibits 67: Chart on Prescription - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on Prescription - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on Prescription - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on Prescription - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on OTC - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on OTC - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on OTC - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on OTC - Year-over-year growth 2023-2028 (%)
Exhibits 75: Market opportunity by Distribution Channel ($ million)
Exhibits 76: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 77: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 78: Impact of drivers and challenges in 2023 and 2028
Exhibits 79: Overview on Criticality of inputs and Factors of differentiation
Exhibits 80: Overview on factors of disruption
Exhibits 81: Impact of key risks on business
Exhibits 82: Vendors covered
Exhibits 83: Matrix on vendor position and classification
Exhibits 84: Absorption Pharmaceuticals LLC - Overview
Exhibits 85: Absorption Pharmaceuticals LLC - Product/Service
Exhibits 86: Absorption Pharmaceuticals LLC - Key offerings
Exhibits 87: Alembic Pharmaceuticals Ltd. - Overview
Exhibits 88: Alembic Pharmaceuticals Ltd. - Product/Service
Exhibits 89: Alembic Pharmaceuticals Ltd. - Key offerings
Exhibits 90: Amneal Pharmaceuticals Inc. - Overview
Exhibits 91: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 92: Amneal Pharmaceuticals Inc. - Key news
Exhibits 93: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 94: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 95: Aytu BioPharma Inc. - Overview
Exhibits 96: Aytu BioPharma Inc. - Product/Service
Exhibits 97: Aytu BioPharma Inc. - Key offerings
Exhibits 98: Bayer AG - Overview
Exhibits 99: Bayer AG - Business segments
Exhibits 100: Bayer AG - Key news
Exhibits 101: Bayer AG - Key offerings
Exhibits 102: Bayer AG - Segment focus
Exhibits 103: Cipla Ltd. - Overview
Exhibits 104: Cipla Ltd. - Business segments
Exhibits 105: Cipla Ltd. - Key news
Exhibits 106: Cipla Ltd. - Key offerings
Exhibits 107: Cipla Ltd. - Segment focus
Exhibits 108: Eli Lilly and Co. - Overview
Exhibits 109: Eli Lilly and Co. - Product/Service
Exhibits 110: Eli Lilly and Co. - Key news
Exhibits 111: Eli Lilly and Co. - Key offerings
Exhibits 112: Johnson and Johnson - Overview
Exhibits 113: Johnson and Johnson - Business segments
Exhibits 114: Johnson and Johnson - Key news
Exhibits 115: Johnson and Johnson - Key offerings
Exhibits 116: Johnson and Johnson - Segment focus
Exhibits 117: NeuroHealing Pharmaceuticals Inc. - Overview
Exhibits 118: NeuroHealing Pharmaceuticals Inc. - Product/Service
Exhibits 119: NeuroHealing Pharmaceuticals Inc. - Key offerings
Exhibits 120: Novartis AG - Overview
Exhibits 121: Novartis AG - Business segments
Exhibits 122: Novartis AG - Key offerings
Exhibits 123: Novartis AG - Segment focus
Exhibits 124: Pfizer Inc. - Overview
Exhibits 125: Pfizer Inc. - Product/Service
Exhibits 126: Pfizer Inc. - Key news
Exhibits 127: Pfizer Inc. - Key offerings
Exhibits 128: Sebela Pharmaceuticals Inc. - Overview
Exhibits 129: Sebela Pharmaceuticals Inc. - Product/Service
Exhibits 130: Sebela Pharmaceuticals Inc. - Key offerings
Exhibits 131: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 132: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 133: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 134: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 135: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 136: Veru Inc. - Overview
Exhibits 137: Veru Inc. - Business segments
Exhibits 138: Veru Inc. - Key offerings
Exhibits 139: Veru Inc. - Segment focus
Exhibits 140: VIVUS LLC - Overview
Exhibits 141: VIVUS LLC - Product/Service
Exhibits 142: VIVUS LLC - Key offerings
Exhibits 143: Inclusions checklist
Exhibits 144: Exclusions checklist
Exhibits 145: Currency conversion rates for US$
Exhibits 146: Research methodology
Exhibits 147: Validation techniques employed for market sizing
Exhibits 148: Information sources
Exhibits 149: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the premature ejaculation disorder market in US: Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Prinston Pharmaceutical Inc., Teva Pharmaceutical Industries Ltd., Veru Inc., VIVUS LLC, Aytu BioPharma Inc., Royalty Pharma plc, and Sebela Pharmaceuticals Inc..

Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is use of nanotechnology in drug delivery.'

According to the report, one of the major drivers for this market is the high efficacy of off-label drugs leading to high usage by people.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Absorption Pharmaceuticals LLC
Alembic Pharmaceuticals Ltd.
Amneal Pharmaceuticals Inc.
Bayer AG
Cipla Ltd.
Eli Lilly and Co.
Johnson and Johnson
Lupin Ltd.
NeuroHealing Pharmaceuticals Inc.
Novartis AG
Pfizer Inc.
Prinston Pharmaceutical Inc.
Teva Pharmaceutical Industries Ltd.
Veru Inc.
VIVUS LLC
Aytu BioPharma Inc.
Royalty Pharma plc
Sebela Pharmaceuticals Inc.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2227EUR$2,500USD£1,900GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€3563EUR$4,000USD£3,040GBP

The premature ejaculation disorder market in US is segmented as below:

By Route Of Administration

By Drug Class

By Distribution Channel

The report on the premature ejaculation disorder market in US covers the following areas:

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Related Topics

Related Reports

Premature Ejaculation Treatment Market 2025-2029

Menstrual Drugs Market 2024-2028

Premature Ejaculation Treatment Market Report 2025

Premature Ejaculation Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

United States Hormone Replacement Therapy Market, By Region, Competition, Forecast & Opportunities, 2020-2030F